Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExAblate BBB Opening with Carboplatin in Recurrent Glioblastoma
jRCTs052220021Phase 2Completed
- Sponsor
- Insightec
- Start
- May 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of carboplatin in glioblastoma (GBM), sponsored by Insightec. Primary endpoints: Safety of BBB opening procedure and Feasibility of BBB opening. Started May 2022; status: completed.
02
Drugs
carboplatin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on jRCTs052220021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs052220021.